Compare Standard Lithium Ltd (SLI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Viatris Inc — how do they compare? Standard Lithium Ltd trades at $2.27 (market cap $523.89M), while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 37.8× Standard Lithium Ltd's market cap, and Viatris Inc pays a 2.83% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| SLI | VTRS | |
|---|---|---|
Market Cap | $523.89M | $19.79B |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $17.39 |
52-Week Low | $2.15 | $8.74 |
Enterprise Value | $383.09M | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $2.15, down 4.87% today, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $48.40 million for 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus remains unanimously bullish with three buy ratings, citing progress toward a final investment decision in 2026.
The investment case hinges on successful project execution, with upside potential from lithium demand and federal funding, but risks include sustained cash burn and delays. The stock's current valuation at 1.52 times book value may attract value investors, yet profitability challenges and bearish technical trends warrant caution amid high operational expenditures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
